⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 21, 2025

Supplementary Figure S5 from Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer

Ya-Yun Cheng Beth L. Worley Zaineb Javed Amal T. Elhaw Priscilla W. Tang Sarah Al-Saad Shriya Kamlapurkar Sierra R. White Apoorva Uboveja Karthikeyan Mythreye Katherine M. Aird Traci A. Czyzyk Nadine Hempel

View Full Paper

Ask AI

Bookmark

Share

Key Points

Loss of the cell adhesion molecule MPZL3 is linked to increased epithelial-mesenchymal transition (EMT) in ovarian cancer.
In vivo experiments show elevated γH2AX expression in tumor tissues, indicating potential DNA damage in ovarian cancer.
EMT plays a crucial role in cancer progression and metastasis, impacting patient prognosis and treatment efficacy.
Understanding MPZL3's role in EMT can lead to novel therapeutic strategies for ovarian cancer.

Implication

In vivo experiments reveal γH2AX expression in tumor tissues, suggesting that loss of MPZL3 enhances EMT in ovarian cancer.

Abstract

Supplementary Figure S5. γH2AX expression in tumor tissues from in vivo experiments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/689a060ee6551bb0af8cd1f1 https://doi.org/10.1158/2767-9764.29607291

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer2025
2Supplementary Figure S2 from Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer2025
3Supplementary Figure S6 from Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer2025
4Supplementary Figure S1 from Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer2025
5Supplementary Figure S4 from Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer2025